Studies have systematically documented over 120 natural therapies that offer relief to one extent or another from neurological conditions. After over two decades of conducting research focused on both Alzheimers and Parkinsons, what is my top recommendation for an Alzheimers treatment?
My answer: photobiomodulation (light therapy). Why you ask?
The gold standard company that first invented photobiomodulation devices with an intranasal applicator is Vielight.com. Twenty-five studies have now been published using a Vielight photobiomodulation device. Every single study reports significant findings for a surprising variety of conditions including Alzheimers.
I first learned about the Vielight photobiomodulation devices from interviewing Vielight’s CEO Dr. Lew Lim in 2018. At that time there was only one published study that reported significant findings for a sample of 5 subjects with early Alzheimers. Today there are 25 published studies using a Vielight photobiomodulation device. All report positive results.
Eight years later, hundreds of members of the Alzheimers Recovery® and Parkinsons Recovery® audiences have used the Neuro Gamma Vielight device. Feedback I have received has been consistently favorable.
There has been an explosion of studies since 2018 that have evaluated photobiomodulation as a treatment for one condition or another. Fifteen hundred (1,500) alone have been published since January 2025.
Vielight.com is the gold standard photobiomodulation company. They offers a generous warranty on all their photobiomodulation devices. If a user does not celebrate relief from symptoms they had anticipated within six months of use, they need only return the device for an 80% refund.
Only 10% of individuals in my audience have returned their device for a refund. The risk of getting one of the Vielight devices is clearly minimal given their generous 80% warranty offered by no other company.
Vielight (https://www.vielight.com) also offers members of the Alzheimers Recovery audience a 10% discount on any of their devices with the coupon code healing4me. Keep in mind that everyone in the family can use the device, not just the person who confronts memory challenges.
The only company to deliver light to the head with a helmet and to the blood stream with a nasal applicator is Vielight.
The following photobiomodulation studies published in 2025 recommend photobiomodulation as a treatment for Alzheimers which is another reason this is my top recommendation for an Alzheimer’s treatment.
2025 Photobiomodulation Alzheimers Studies
Photobiomodul Photomed Laser Surg. 2025 Sep;43(9):411-416. The Efficacy and Safety of Transcranial Photobiomodulation for Mild Cognitive Impairment Due to Alzheimer’s Disease: A Randomized, Double-Blind, Sham-Controlled Study
Abstract
Background: Transcranial photobiomodulation (tPBM) is a promising noninvasive neuromodulation modality with potential therapeutic benefits for neurodegenerative diseases. Infrared light delivered by a tPBM device penetrates the cortex, stimulating neuronal activity by increasing mitochondrial adenosine triphosphate production and enhancing regional cerebral blood flow.
Objective: This study investigated the efficacy and safety of a self-administered, at-home, wearable tPBM device for improving cognitive function in individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD).
Methods: Individuals with MCI due to AD, diagnosed according to the National Institute on Aging and Alzheimer’s Association criteria, with a Korean version of Mini-Mental State Examination-2 (K-MMSE2) score of 23-27 and a global Clinical Dementia Rating (CDR) score of 0.5-1.0 were enrolled. Subjects self-administered tPBM six times per week for 12 weeks. Assessments were conducted at weeks 7 and 13 using the Korean version of the Montreal Cognitive Assessment (K-MoCA), K-MMSE2, the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease, and the Geriatric Depression Scale.
Results: A total of 26 participants were enrolled. The treatment group showed a statistically significant improvement in K-MoCA scores at week 13 (p < 0.05) compared with the sham group. Although K-MMSE2 scores improved in the treatment group, the difference was not statistically significant. No serious adverse events were reported.
Conclusion: Findings suggest that tPBM is an effective and safe home-use intervention for individuals with MCI, with promising therapeutic and preventative roles in Alzheimer’s dementia.
******
Lasers Med Sci. 2025 Nov 15;40(1):480. Transcranial photobiomodulation therapy in older women regarding cognitive functions: a systematic review
Abstract
Transcranial photobiomodulation therapy (tPBM) is a promising non-invasive treatment that uses red or near-infrared light to modulate biological functions and elicit therapeutic effects.
This systematic review aimed to summarize the evidence on the effectiveness of tPBM in improving cognitive function in older women, in experimental animal models and in humans, by analyzing the optimal tPBM parameters and behavioral and neurobiological outcomes.
tPBM offers advantages specific to older women as a non-invasive brain stimulation technique, applied to a sensitive population with increased risk of aging-related brain dysfunction due to increased life expectancy.
A comprehensive literature search was conducted in PubMed, Scopus, and PsycINFO databases, and only seven articles on older women were included in the review. Studies have shown that tPBM significantly improves cognitive impairment in Alzheimer’s disease and related dementias, stroke, cognition and Parkinson’s disease in older women. Despite the heterogeneity in the application parameters and limited number of studies, tPBM therapy was preliminarily found to be a safe, feasible, and effective non-pharmacological therapy for several neurological and mental health conditions in older women
J Alzheimers Dis. 2025 Sep;107(2):529-541. Improved cognitive function, efficiency, saccadic eye movement, and depressive symptoms in mild cognitive impairment with transcranial photobiomodulation
Abstract
Background. Mild cognitive impairment (MCI) is a critical stage with higher progression to Alzheimer’s disease, yet effective interventions are still lacking.
Objective. Some empirical studies have shown that transcranial photobiomodulation (tPBM) may be effective in enhancing cognitive function. To further investigate its effectiveness, a controlled experiment was conducted.
Methods. In this study, 36 community-dwelling older adults with MCI were assigned to receive either real tPBM (experimental group; n = 25) and others without intervention (control group; n = 11) over three weeks. Participants underwent comprehensive assessments before and after the intervention, including neuropsychological tests, measurements of oxygenated hemoglobin (HbO) using function near-infrared spectroscopy during a visual working memory task, saccadic movement measurement using an eye-tracking device, and a questionnaire assessing depressive symptoms.
Results. Compared to the control group, the experimental group demonstrated significant improvements. They showed enhanced cognitive efficiency, as evidenced by improved visual working memory performance, reduced anti-saccade latency, higher scores in the Montreal Cognitive Assessment, and faster completion time in the Shape Trail Test B. In addition, significantly more participants in the experimental group showed improvement in depressive symptoms after the intervention.
Conclusions. These findings provide evidence that tPBM may effectively improve neuropsychological, physiological, and psychological outcomes in individuals with mild cognitive impairment .
Robert Rodgers PhD
Founder 2005
Alzheimers Recovery®
https://www.alzheimersrecovery.com
robert@alzheimersrecovery.com